Drug
Lubiprostone clinical trials
Also written Amitiza.
- studies test it
- 46
- open now
- 2
- in phase 3
- 22
- first study started
- 2005
Keep track of what changes. Save the Lubiprostone studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Amitiza
- 28
Combined with it in one product
Studies by the year they started
46 studies that test it; most in 2007 (7)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2007 | 7 |
| 2008 | 6 |
| 2009 | 5 |
| 2010 | 7 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 1 |
| 2020 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 5
- Phase 3
- 22
- Phase 4
- 11
- No phase
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 27
Sucampo Pharma Americas, LLC (13) · Takeda (3) · University of South Alabama (2) · Augusta University (2) · Texas Tech University Health Sciences Center, El Paso (2) · Mayo Clinic (2) · Brooke Army Medical Center (2) · University of Arkansas (2)
Often tested with
Tested in the same studies.
Polyethylene glycol 3350 (1) · Polyethylene Glycols (1) · Bisacodyl (1) · Golytely (1) · Maintenance Therapy (1)
Studies
Open first, then newest update. How each study uses Lubiprostone is read from its arms, and is right about nine times in ten.
Testing it · 46
- Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit ConstipationRecruitingPhase 3Third Military Medical UniversityNCT07277907Written as Lubiprostone
- Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal CancerNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07405736Written as maintenance therapy plus lubiprostone
- Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver DiseaseCompletedPhase 3Helwan UniversityNCT05768334Written as Lubiprostone 24Mcg Oral twice daily
- Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral TherapyCompletedPhase 2Ruth M. Rothstein CORE CenterNCT01839734Written as Lubiprostone
- Amitiza® Plus GoLYTELY® (PEG) Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy PreparationCompletedPhase 4Henry Ford Health SystemNCT00645801Written as lubiprostone (Amitiza)
- Amitiza in Constipation Associated With PD (Parkinson's Disease)CompletedPhase 4Baylor College of MedicineNCT00908076Written as LUBIPROSTONE
- Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating MedicationsTerminatedPhase 4University of South AlabamaNCT01096290Written as lubiprostone
- Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule EndoscopyCompletedPhase 4University of South AlabamaNCT00746395Written as Lubiprostone
- Lubiprostone in Children With Functional ConstipationCompletedPhase 3Sucampo Pharma Americas, LLCNCT02042183Written as Lubiprostone
- Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional ConstipationCompletedPhase 3Sucampo Pharma Americas, LLCNCT02766777Written as Lubiprostone
- Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy VolunteersCompletedPhase 3Sucampo Pharma Americas, LLCNCT03010631Written as Cohort 1: Lubiprostone Capsule, Fasted
- Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)CompletedPhase 3Sucampo Pharma Americas, LLCNCT01298219Written as Lubiprostone
- Lubiprostone for Children With ConstipationCompletedPhase 3Sucampo Pharma Americas, LLCNCT02138136Written as Lubiprostone
- Opioid-induced Bowel Dysfunction: Long-Term Assessment of LubiprostoneCompletedPhase 3Sucampo Pharma Americas, LLCNCT00620061Written as Lubiprostone 24
- Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to PlaceboCompletedPhase 3Sucampo Pharma Americas, LLCNCT03097861Written as Lubiprostone
- Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel SyndromeTerminatedPhase 2Sucampo Pharma Americas, LLCNCT02544152Written as Lubiprostone
- Safety and Efficacy of Lubiprostone in Pediatric Patients With ConstipationCompletedPhase 4Sucampo Pharma Americas, LLCNCT00452335Written as Lubiprostone
- Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With ConstipationCompletedPhase 3Sucampo Pharma Americas, LLCNCT00399542Written as Lubiprostone
- Opioid-induced Bowel Dysfunction: Pivotal Assessment of LubiprostoneCompletedPhase 3Sucampo Pharma Americas, LLCNCT00595946Written as Lubiprostone
- Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic ConstipationCompletedPhase 3MallinckrodtNCT01993875Written as Lubiprostone
See all 46 studies that test Lubiprostone →
As the comparator · 1 — what is tested is compared with Lubiprostone
Codes
What other systems call Lubiprostone · ClinicalTrials.gg INT006502
- MeSH (NLM) D000068238LubiprostoneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 7662KG2R6KLUBIPROSTONEConfirmed FDA, NLM, Wikidata
- RxNorm 623033Confirmed FDA, Wikidata
- Wikidata Q6695342lubiprostoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66040LubiprostoneConfirmed FDA, Wikidata
- DrugBank DB01046One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068238 | Lubiprostone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 7662KG2R6K | LUBIPROSTONE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 623033 | — | Confirmed FDA, Wikidata |
| Wikidata | Q6695342 | lubiprostone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66040 | Lubiprostone | Confirmed FDA, Wikidata |
| DrugBank | DB01046 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.